American Journal of Ophthalmology
Volume 148, Issue 4 , Pages 487-499.e2 , October 2009

Acanthamoeba Keratitis: Diagnosis and Treatment Update 2009

  • John K.G. Dart

      Affiliations

    • Corneal and External Disease Service, Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
    • Department of Pathology, Institute of Ophthalmology, University College London, London, United Kingdom
    • Corresponding Author InformationInquiries to John K. G. Dart, Moorfields Eye Hospital NHS Foundation Trust, 162 City Road, London, EC1V 2PD, United Kingdom
    • ,
  • Valerie P.J. Saw

      Affiliations

    • Corneal and External Disease Service, Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
    • ,
  • Simon Kilvington

      Affiliations

    • Department of Infection, Immunity & Inflammation, University of Leicester, Leicester, United Kingdom
    • Abbott Medical Optics, Santa Ana, California

,Accepted 1 June 2009.

References 

  1. Awwad ST, Petroll WM, McCulley JP, Cavanagh HD. Updates in Acanthamoeba keratitis. Eye Contact Lens. 2007;33:1–8
  2. Hammersmith KM. Diagnosis and management of Acanthamoeba keratitis. Curr Opin Ophthalmol. 2006;17:327–331
  3. Illingworth CD, Cook SD. Acanthamoeba keratitis. Surv Ophthalmol. 1998;42:493–508
  4. Alizadeh H, Apte S, El Agha MS, et al. Tear IgA and serum IgG antibodies against Acanthamoeba in patients with Acanthamoeba keratitis. Cornea. 2001;20:622–627
  5. Ibrahim YW, Boase DL, Cree IA. Factors affecting the epidemiology of Acanthamoeba keratitis. Ophthalmic Epidemiol. 2007;14:53–60
  6. Watson S, Dart JKG. Acanthamoeba keratitis. In:  Johnson GJ,  Minassian D,  Weale RA,  West SK editor. The Epidemiology of Eye Disease. London, England: Arnold; 2003;p. 200–205
  7. Srinivasan M, Gonzales CA, George C, et al. Epidemiology and aetiological diagnosis of corneal ulceration in Madurai, South India. Br J Ophthalmol. 1997;81:965–971
  8. Bharathi MJ, Ramakrishnan R, Meenakshi R, Padmavathy S, Shivakumar C, Srinivasan M. Microbial keratitis in South India: influence of risk factors, climate, and geographical variation. Ophthalmic Epidemiol. 2007;14:61–69
  9. Houang E, Lam D, Fan D, Seal D. Microbial keratitis in Hong Kong: relationship to climate, environment and contact-lens disinfection. Trans R Soc Trop Med Hyg. 2001;95:361–367
  10. Butler TK, Males JJ, Robinson LP, et al. Six-year review of Acanthamoeba keratitis in New South Wales, Australia: 1997–2002. Clin Experiment Ophthalmol. 2005;33:41–46
  11. Acharya NR, Lietman TM, Margolis TP. Parasites on the rise: a new epidemic of Acanthamoeba keratitis. Am J Ophthalmol. 2007;144:292–293
  12. Stehr-Green JK, Bailey TM, Visvesvara GS. The epidemiology of Acanthamoeba keratitis in the United States. Am J Ophthalmol. 1989;107:331–336
  13. Radford CF, Minassian DC, Dart JK. Acanthamoeba keratitis in England and Wales: incidence, outcome, and risk factors. Br J Ophthalmol. 2002;86:536–542
  14. Sharma S, Garg P, Rao GN. Patient characteristics, diagnosis, and treatment of non-contact lens related Acanthamoeba keratitis. Br J Ophthalmol. 2000;84:1103–1108
  15. Kilvington S, Gray T, Dart J, et al. Acanthamoeba keratitis: the role of domestic tap water contamination in the United Kingdom. Invest Ophthalmol Vis Sci. 2004;45:165–169
  16. Mathers WD, Sutphin JE, Lane JA, Folberg R. Correlation between surface water contamination with amoeba and the onset of symptoms and diagnosis of amoeba-like keratitis. Br J Ophthalmol. 1998;82:1143–1146
  17. Radford CF, Lehmann OJ, Dart JK. Acanthamoeba keratitis: multicentre survey in England 1992–1996. National Acanthamoeba Keratitis Study Group. Br J Ophthalmol. 1998;82:1387–1392
  18. Watt KG, Swarbrick HA. Trends in microbial keratitis associated with orthokeratology. Eye Contact Lens. 2007;33:373–377
  19. Joslin CE, Tu EY, Shoff ME, et al. The association of contact lens solution use and Acanthamoeba keratitis. Am J Ophthalmol. 2007;144:169–180
  20. Joslin CE, Tu EY, McMahon TT, Passaro DJ, Stayner LT, Sugar J. Epidemiological characteristics of a Chicago-area Acanthamoeba keratitis outbreak. Am J Ophthalmol. 2006;142:212–217
  21. Jeong HJ, Lee SJ, Kim JH, et al. Acanthamoeba: keratopathogenicity of isolates from domestic tap water in Korea. Exp Parasitol. 2007;117:357–367
  22. Dart JK, Radford CF, Minassian D, Verma S, Stapleton F. Risk factors for microbial keratitis with contemporary contact lenses: a case-control study. Ophthalmology. 2008;115:1647–1654
  23. Stapleton F, Keay L, Edwards K, et al. The incidence of contact lens-related microbial keratitis in Australia. Ophthalmology. 2008;115:1655–1662
  24. Clarke DW, Niederkorn JY. The pathophysiology of Acanthamoeba keratitis. Trends Parasitol. 2006;22:175–180
  25. Clarke DW, Niederkorn JY. The immunobiology of Acanthamoeba keratitis. Microbes Infect. 2006;8:1400–1405
  26. Clarke DW, Alizadeh H, Niederkorn JY. Failure of Acanthamoeba castellanii to produce intraocular infections. Invest Ophthalmol Vis Sci. 2005;46:2472–2478
  27. Van Klink F, Taylor WM, Alizadeh H, Jager MJ, van Rooijen N, Niederkorn JY. The role of macrophages in Acanthamoeba keratitis. Invest Ophthalmol Vis Sci. 1996;37:1271–1281
  28. Hurt M, Apte S, Leher H, Howard K, Niederkorn J, Alizadeh H. Exacerbation of Acanthamoeba keratitis in animals treated with anti-macrophage inflammatory protein 2 or antineutrophil antibodies. Infect Immun. 2001;69:2988–2995
  29. McClellan K, Howard K, Niederkorn JY, Alizadeh H. Effect of steroids on Acanthamoeba cysts and trophozoites. Invest Ophthalmol Vis Sci. 2001;42:2885–2893
  30. Van Klink F, Leher H, Jager MJ, Alizadeh H, Taylor W, Niederkorn JY. Systemic immune response to Acanthamoeba keratitis in the Chinese hamster. Ocul Immunol Inflamm. 1997;5:235–244
  31. Van Klink F, Alizadeh H, He Y, et al. The role of contact lenses, trauma, and Langerhans cells in a Chinese hamster model of Acanthamoeba keratitis. Invest Ophthalmol Vis Sci. 1993;34:1937–1944
  32. Yang YF, Matheson M, Dart JK, Cree IA. Persistence of Acanthamoeba antigen following Acanthamoeba keratitis. Br J Ophthalmol. 2001;85:277–280
  33. McClellan K, Howard K, Mayhew E, Niederkorn J, Alizadeh H. Adaptive immune responses to Acanthamoeba cysts. Exp Eye Res. 2002;75:285–293
  34. Lee GA, Gray TB, Dart JK, et al. Acanthamoeba sclerokeratitis: treatment with systemic immunosuppression. Ophthalmology. 2002;109:1178–1182
  35. Awwad ST, Heilman M, Hogan RN, et al. Severe reactive ischemic posterior segment inflammation in Acanthamoeba keratitis: a new potentially blinding syndrome. Ophthalmology. 2007;114:313–320
  36. Claerhout I, Goegebuer A, van Den BC, Kestelyn P. Delay in diagnosis and outcome of Acanthamoeba keratitis. Graefes Arch Clin Exp Ophthalmol. 2004;242:648–653
  37. Bacon AS, Dart JK, Ficker LA, Matheson MM, Wright P. Acanthamoeba keratitis (The value of early diagnosis). Ophthalmology. 1993;100:1238–1243
  38. Tu EY, Joslin CE, Sugar J, Shoff ME, Booton GC. Prognostic factors affecting visual outcome in Acanthamoeba keratitis. Ophthalmology. 2008;115:1998–2003
  39. Bacon AS, Frazer DG, Dart JK, Matheson M, Ficker LA, Wright P. A review of 72 consecutive cases of Acanthamoeba keratitis, 1984–1992. Eye. 1993;7:719–725
  40. Sun X, Zhang Y, Li R, et al. Acanthamoeba keratitis: clinical characteristics and management. Ophthalmology. 2006;113:412–416
  41. Mathers WD, Goldberg MA, Sutphin JE, Ditkoff JW, Folberg R. Coexistent Acanthamoeba keratitis and herpetic keratitis. Arch Ophthalmol. 1997;115:714–718
  42. Murthy S, Hawksworth NR, Cree I. Progressive ulcerative keratitis related to the use of topical chlorhexidine gluconate (0.02%). Cornea. 2002;21:237–239
  43. Herz NL, Matoba AY, Wilhelmus KR. Rapidly progressive cataract and iris atrophy during treatment of Acanthamoeba keratitis. Ophthalmology. 2008;115:866–869
  44. Mathers WD. Acanthamoeba: a difficult pathogen to evaluate and treat. Cornea. 2004;23:325
  45. Parmar DN, Awwad ST, Petroll WM, Bowman RW, McCulley JP, Cavanagh HD. Tandem scanning confocal corneal microscopy in the diagnosis of suspected Acanthamoeba keratitis. Ophthalmology. 2006;113:538–547
  46. Tu EY, Joslin CE, Sugar J, Booton GC, Shoff ME, Fuerst PA. The relative value of confocal microscopy and superficial corneal scrapings in the diagnosis of Acanthamoeba keratitis. Cornea. 2008;27:764–772
  47. Lehmann OJ, Green SM, Morlet N, et al. Polymerase chain reaction analysis of corneal epithelial and tear samples in the diagnosis of Acanthamoeba keratitis. Invest Ophthalmol Vis Sci. 1998;39:1261–1265
  48. Mathers WD, Nelson SE, Lane JL, Wilson ME, Allen RC, Folberg R. Confirmation of confocal microscopy diagnosis of Acanthamoeba keratitis using polymerase chain reaction analysis. Arch Ophthalmol. 2000;118:178–183
  49. Duguid IG, Dart JK, Morlet N, et al. Outcome of Acanthamoeba keratitis treated with polyhexamethyl biguanide and propamidine. Ophthalmology. 1997;104:1587–1592
  50. Elder MJ, Kilvington S, Dart JK. A clinicopathologic study of in vitro sensitivity testing and Acanthamoeba keratitis. Invest Ophthalmol Vis Sci. 1994;35:1059–1064
  51. Schuster FL, Visvesvara GS. Opportunistic amoebae: challenges in prophylaxis and treatment. Drug Resist Updat. 2004;7:41–51
  52. Bouyer S, Imbert C, Daniault G, Cateau E, Rodier MH. Effect of caspofungin on trophozoites and cysts of three species of Acanthamoeba. J Antimicrob Chemother. 2007;59:122–124
  53. Schuster FL, Guglielmo BJ, Visvesvara GS. In-vitro activity of miltefosine and voriconazole on clinical isolates of free-living amoebas: Balamuthia mandrillaris, Acanthamoeba spp., and Naegleria fowleri. J Eukaryot Microbiol. 2006;53:121–126
  54. Nacapunchai D, Phadungkul K, Kaewcharus S. In vitro effect of artesunate against Acanthamoeba spp. Southeast Asian J Trop Med Public Health. 2002;33:S49–S52
  55. Mathers W. Use of higher medication concentrations in the treatment of Acanthamoeba keratitis. Arch Ophthalmol. 2006;124:923
  56. Rahman MR, Minassian DC, Srinivasan M, Martin MJ, Johnson GJ. Trial of chlorhexidine gluconate for fungal corneal ulcers. Ophthalmic Epidemiol. 1997;4:141–149
  57. Seal DV. Acanthamoeba keratitis update-incidence, molecular epidemiology and new drugs for treatment. Eye. 2003;17:893–905
  58. Kilvington S, Hughes R, Byas J, Dart J. Activities of therapeutic agents and myristamidopropyl dimethylamine against Acanthamoeba isolates. Antimicrob Agents Chemother. 2002;46:2007–2009
  59. Larkin DF, Kilvington S, Dart JK. Treatment of Acanthamoeba keratitis with polyhexamethylene biguanide. Ophthalmology. 1992;99:185–191
  60. Hay J, Kirkness CM, Seal DV, Wright P. Drug resistance and Acanthamoeba keratitis: the quest for alternative antiprotozoal chemotherapy. Eye. 1994;8:555–563
  61. Perez-Santonja JJ, Kilvington S, Hughes R, Tufail A, Matheson M, Dart JK. Persistently culture positive Acanthamoeba keratitis: in vivo resistance and in vitro sensitivity. Ophthalmology. 2003;110:1593–1600
  62. Larkin DF, Berry M, Easty DL. In vitro corneal pathogenicity of Acanthamoeba. Eye. 1991;5:560–568
  63. Lim N, Goh D, Bunce C, et al. Comparison of polyhexamethylene biguanide and chlorhexidine as monotherapy agents in the treatment of Acanthamoeba keratitis. Am J Ophthalmol. 2008;145:130–135
  64. Kosrirukvongs P, Wanachiwanawin D, Visvesvara GS. Treatment of Acanthamoeba keratitis with chlorhexidine. Ophthalmology. 1999;106:798–802
  65. Perrine D, Chenu JP, Georges P, Lancelot JC, Saturnino C, Robba M. Amoebicidal efficiencies of various diamidines against two strains of Acanthamoeba polyphaga. Antimicrob Agents Chemother. 1995;39:339–342
  66. Radford CF, Bacon AS, Dart JK, Minassian DC. Risk factors for Acanthamoeba keratitis in contact lens users: a case-control study. BMJ. 1995;310:1567–1570
  67. Park DH, Palay DA, Daya SM, Stulting RD, Krachmer JH, Holland EJ. The role of topical corticosteroids in the management of Acanthamoeba keratitis. Cornea. 1997;16:277–283
  68. Matoba AY, Pare PD, Le TD, Osato MS. The effects of freezing and antibiotics on the viability of Acanthamoeba cysts. Arch Ophthalmol. 1989;107:439–440
  69. Binder PS. Cryotherapy for medically unresponsive Acanthamoeba keratitis. Cornea. 1989;8:106–114
  70. Chen WL, Wu CY, Hu FR, Wang IJ. Therapeutic penetrating keratoplasty for microbial keratitis in Taiwan from 1987 to 2001. Am J Ophthalmol. 2004;137:736–743
  71. Ficker LA, Kirkness C, Wright P. Prognosis for keratoplasty in Acanthamoeba keratitis. Ophthalmology. 1993;100:105–110
  72. Kashiwabuchi RT, de Freitas D, Alvarenga LS, et al. Corneal graft survival after therapeutic keratoplasty for Acanthamoeba keratitis. Acta Ophthalmol. 2008;86:666–669
  73. Sony P, Sharma N, Vajpayee RB, Ray M. Therapeutic keratoplasty for infectious keratitis: a review of the literature. CLAO J. 2002;28:111–118
  74. Awwad ST, Parmar DN, Heilman M, Bowman RW, McCulley JP, Cavanagh HD. Results of penetrating keratoplasty for visual rehabilitation after Acanthamoeba keratitis. Am J Ophthalmol. 2005;140:1080–1084
  75. Ishibashi Y, Matsumoto Y, Kabata T, et al. Oral itraconazole and topical miconazole with debridement for Acanthamoeba keratitis. Am J Ophthalmol. 1990;109:121–126
  76. Seal D, Hay J, Kirkness C, et al. Successful medical therapy of Acanthamoeba keratitis with topical chlorhexidine and propamidine. Eye. 1996;10:413–421
  77. Azuara-Blanco A, Sadiq AS, Hussain M, Lloyd JH, Dua HS. Successful medical treatment of Acanthamoeba keratitis. Int Ophthalmol. 1997;21:223–227
  78. Hargrave SL, McCulley JP, Husseini Z. Results of a trial of combined propamidine isethionate and neomycin therapy for Acanthamoeba keratitis (Brolene Study Group). Ophthalmology. 1999;106:952–957
  79. Thebpatiphat N, Hammersmith KM, Rocha F, et al. Acanthamoeba keratitis: a parasite on the rise. Cornea. 2007;26:701–706
  80. Allan BD, Dart JK. Strategies for the management of microbial keratitis. Br J Ophthalmol. 1995;79:777–786

 Supplemental Material available at AJO.com.

PII: S0002-9394(09)00409-7

doi: 10.1016/j.ajo.2009.06.009

American Journal of Ophthalmology
Volume 148, Issue 4 , Pages 487-499.e2 , October 2009

Article Tools

* Image Usage & Resolution